SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Magnifier magnifying exclamation mark on red background. Alert and precaution concept. Caution and risk management security signal announcement hazard and dangerous notice symbol
Regulatory
FDA Ties Amgen’s Rare Inflammatory Disease Drug to Eight Deaths, Dozens of Liver Injuries
The FDA in January asked Amgen to pull Tavneos from the market, citing liver toxicity issues that affected the drug’s overall risk-benefit profile. The pharma refused.
April 1, 2026
 · 
2 min read
 · 
Tristan Manalac
3d render, open blue door isolated on blue background, yellow light going through the slot. Architectural design element. Modern minimal concept. Opportunity metaphor.
Company closure
IO Shuts Down Following Regulatory Roadblocks
The FDA advised IO Biotech last year to hold off on filing an approval application for its cancer vaccine Cylembio, pointing to a failed Phase 3 study in frontline advanced melanoma. The biotech has now gone under.
April 1, 2026
 · 
2 min read
 · 
Tristan Manalac
3D rendering of a Syringe Shield and multiple instances of the international radioactive hazard symbol or the trefoil icon.
Insights
The Brave New World of Radiotherapeutics
Convergent Therapeutics’ Dr. Philip Kantoff and Plus Therapeutics’ Dr. Marc Hedrick discuss how unmet medical needs, maturing isotope supply chains and innovative delivery are positioning targeted radiation as oncology’s next big platform.
April 1, 2026
 · 
4 min read
 · 
Jennifer C. Smith-Parker
Neon tunnel leading to futuristic city
Career Advice
3 Career Moves R&D Professionals Must Make in a Skills-Based, AI-Driven Economy
As AI reshapes deeply specialized scientific work, R&D professionals must learn to navigate the shift to a skills-centered market. The key is knowing which skills to develop and how to leverage AI as scientific modalities evolve, technologies advance and regulatory complexity increases.
April 1, 2026
 · 
5 min read
 · 
Kenneth Munie
Pills, capsules and tablets that shape the map of the world, as a symbol for global medicine issues. Vector illustration.
Drug pricing
Trump’s MFN Pricing Expected To Delay More European Drug Launches
Following Insmed’s decision to hold off on launching a newly approved lung disease drug in Europe, experts anticipate more companies will do the same as they seek to avoid price erosion in the U.S. Will Chinese biotechs fill the void?
April 1, 2026
 · 
3 min read
 · 
Nick Paul Taylor
Robot sits at big arrow, symbolising a growth of AI technology. 3D rendering
Artificial intelligence
Biotech IPOs Rebound as AI Takes a More Central Role in Drug Development
The recent uptick in IPOs is an encouraging signal after a drought for much of 2025. Experts point to AI as a driving force behind this resurgence.
April 1, 2026
 · 
6 min read
 · 
Tristan Manalac
Decorative border of fly different flavor ice cream cones in waffle - white, pink, brown with chocolate sauce on pink.
Mergers & acquisitions
Pharma Double-Dippers Lead Q1 Deal Activity to Nearly $47B
Deal-hungry Big Pharmas, a long-sought biotech prize, an infrequent buyer and one serial biotech rabblerouser highlight a busy quarter in biopharma M&A.
April 1, 2026
 · 
1 min read
 · 
Annalee Armstrong
Businessman in starting position ready to sprint run stock illustration
Mergers & acquisitions
Biogen Secures ‘Running Start’ in Kidney Disease With $5.6B Apellis Buy
In addition to delivering two approved medicines to Biogen’s portfolio, the acquisition of Apellis Pharmaceuticals will support the future launch of the pharma’s own kidney disease asset, currently in multiple Phase 3 trials.
March 31, 2026
 · 
4 min read
 · 
Annalee Armstrong
Illustration showing a downward graph trend
Rare diseases
PepGen Loses Half of Share Price on Mixed Data in Rare Muscle-Wasting Disease
PepGen’s lead candidate for myotonic dystrophy type 1 barely beat the placebo in a Phase 2 trial in terms of fixing incorrect gene splicing, but the biotech attributed the poor result to an outlier.
March 31, 2026
 · 
2 min read
 · 
Heather McKenzie
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS